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1. Introduction 
Migraine headaches affect approximately 13% of US population, affecting women in a 3:1 
ratio and with a 60–80% familial inheritance. Migraine is a relevant social health problem; in 
fact it significantly restricts the social life of those who are affected. Recently, migraine 
headache has been suspected to be a potential risk factor for stroke, particularly in women, 
smokers and for those making use of oral contraception. 
Onset of migraine is usually between the ages of 20–64, with over 80% having their first 
episode before age 30 and tends to decrease in middle age. Migraine with aura (MA) is a 
variant characterized by transient neurological visual, verbal, sensory or motor symptoms 
that last from five to sixty minutes. MA is also known as “classic migraine” though only 
25% of migraneurs experience an aura. 
Increased frequency of patent foramen Ovale (PFO) in migraneurs was first reported in 1998 
in a case–control study. 
An increased prevalence between patent foramen Ovale (PFOs) and migraine exists but 
there is conflicting data of a causal relationship between these two conditions. It remains 
controversial whether cardiac screening and intervention provides a treatment benefit in 
migraneurs and is an area currently investigated for demonstrating clinical benefit of PFO 
closure. This topic is an intersection between the practice of primary care physicians, 
neurologists, and cardiologists on the best practice and management of patients with 
difficult to control migraines given the billions spent on physician visits and 
pharmacotherapy. 
Several mechanisms linking PFO to migraine have been hypothesized, including humoral 
causes (serotonin-platelet activation, aggregation, and embolism causing cortical spreading 
depression) and genetic causes (autosomal dominant inheritance with incomplete 
penetrance). The presence of a right to left shunt (RLS) may be the most potent trigger of 
migraine attacks with or without aura, and researchers have speculated that a large RLS 
may contribute to the high risk of ischemic stroke in migraneurs with PFO. 
Diagnostic Modalities to evaluate the presence or absence of PFO in the migraine patients 
are another controversial subject. Mostly agree that the Trans –thoracic echocardiography is 
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less sensitive test particularly in adolescents and adults. Trans- Esophageal and Intra-
Cardiac Echocardiography carry more reliability in detecting left to right shunt. Recently 
Trans-Cranial Doppler has been postulated as more accurate test to detect the right to left 
shunting in those patients. 
PFO closure (particularly device closure) carries the most controversial issue in this subject. 
With only –so far- one randomized large clinical trial and several prospective cohorts and 
case control studies, there is conflicting data about the benefit of PFO closure in relieving or 
treating the Migraine headache. 
This chapter will talk first about the anatomy and physiology of Patent Foramen Ovale in 
normal population, anatomical variants of the PFO, the current diagnostic methods used by 
different institutions then seeks to summarize the current literature on the association of 
PFO and migraine headache and studies that have investigated PFO closure in this 
population. 
1.1 Definitions 
The topic of Migraine headache in association with Patent Foramen Ovale (PFO) has been 
one of the controversial topics in the literature. Since 1998 when the first scientific 
observation that patients with migraine headaches have higher prevelance of PFO(1), the 
dogma between causation, association and prevention has continued.  
In order to make reading through this chapter easier, some definitions will be instated: 
2. Patent foramen ovale in normal population 
Several studies reported high prevalence of PFO in normal subjects. The highest prevalence 
reported was in autopsy studies. With a probe inserted in the region of the foremen ovale, if 
the probe can be passed through it then he/she will be labeled to have PFO. Such studies 
reported incidence of 25% (2). While looking for the incidence of PFO in Normal population by 
Trans Esophageal Echocardiogram reported to be less than autopsy studies about 15% (3-4). 
The foramen ovale is composed of the septum primum and the septum secundum joined in 
parallel, forming a tunnel-like structure allowing the oxygenated blood from the placenta to 
pass towards the systemic circulation. Postnatally, it closes with a valve-like mechanism. 
Patent foramen ovale results from lack of post neonatal closure. Under certain 
hemodynamic conditions, when there is a transient pressure gradient from the right to left 
atria, a PFO can open and enable blood or any blood borne substances to pass from the 
venous to the arterial circulation. This process is the mechanism of paradoxical embolism, 
which has been frequently reported in the literature (5-8). There are multiple anatomical 
variants of PFO morphology (figure 1). Occasionally the PFO has an association with atrial 
septal aneurysm (figure 2). These variants and atrial aneurysm has been believed to play a 
major role of the amount and the direction of shunt across the PFO.  
3. Migraine headache 
Migraine is a common, disabling, largely inherited neurological disorder with a prevalence of 8% 
to 13% in the population of the Western hemisphere (9, 10), with a 3:1 female preponderance.  
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Fig. 1. Several Morphologies of Patent Foramen Ovale. a: the common type of PFO with a 
tunnel (white arrows) that can stretch with Valsava. b: Multi fenestration defects in the PFO 
region. c: a deficient part of the secundum septum covering the PFO from the left side of the 
atrial septum. 
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Fig. 2. Echocardiographic appearance of different PFO morphologies, a: Intra Cardiac Echo 
(ICE) of a tunnel shape PFO. b: Large atrial aneurysm (orange arrow heads) by trans 
thoracic echo(TTE). c: small multi fenestration by TTE color Doppler. d: larger fenestrations 
by TEE color Doppler. 
Migraine is a common, chronic, disabling neurovascular disorder characterized by attacks of 
severe headache, autonomic nervous system dysfunction, and, in some patients, an aura and 
neurological symptoms (11). The suffering associated with migraine headaches accounts for a 
significant loss in productivity and a substantial increase in healthcare-related costs. About 
60% of the patients with Migraine reported that they can’t go to work while having the 
headache. In approximately one third of sufferers, an aura—consisting of reversible 
neurological symptoms such as visual illusions, unilateral paresthesias, and 
expressive/receptive language dysfunction—will precede or occur during some attacks. A 
typical migraneurs has one to two attacks per month, with a median duration of 24 hours. In 
addition, approximately 2% of the population experiences a more disabling form of migraine, 
known as chronic migraine, which is characterized by headache on more than 15 days/month. 
The diagnosis of migraine is purely clinical, and its physiopathology is complex and not 
fully understood, with both genetic and environmental factors appearing to play an 
important role. Genetic effects, including autosomal dominant inheritance with incomplete 
penetrance (12, 15) and coinheritance, (13) have also been reported.  
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The prevailing hypothesis regarding the pathogenesis of migraine is an inherited excitability of 
certain brain networks that, when triggered by particular endogenous or exogenous factors, 
leads to a cascade of events that result in head pain, in addition to a multitude of other 
symptoms, including a heightened sensitivity to movement and ambient light, noise, and 
odor; nausea; emesis; cognitive impairment; vertigo; depression; and lethargy (14). Commonly 
used preventive medications such as Propranolol, Amitryptiline or anticonvulsants reduce 
headache frequency in the range of 30-50%, as compared to placebo (16-17).  
Migraine occurs in about 15% of the pediatric population, with approximately 
One-third of cases associated with an aura (18). 
3.1 The association of migraine headache and patent foramen ovale 
The initial observation of this association came from the studies of vascular embolic strokes 
and PFO. The initial observation of increased prevalence of PFO in migraneurs came out in 
1998 (1). Then subsequently several studies looked specifically for the prevalence of PFO in 
Migraneurs. Anzola and colleagues performed a case control study including 113 
consecutive patients with migraine with aura, 53 patients with migraine without aura and 
25 ages matched no migraine subjects. The presence of PFO was assessed indirectly by using 
transcranial Doppler sonography with IV. Injection of agitated saline. The prevalence of 
PFO was 48% in patients with migraine with aura, 23% in patients with migraine without 
aura and 20% in controls. The difference between migraine with aura and migraine without 
aura was significant (odds ratio=3.13) as well as between migraine with aura and control 
group (odds ratio=3.66) (19).  
Schwedt et al. (2008) performed a systematic review of 18 out of 134 identified articles to 
examine the prevalence of migraine in patients with PFO. The results demonstrated that 
people with migraine with aura are more likely to have a PFO than people with migraine 
without aura or healthy controls (20). Migraine with aura not related with diving occurred 
significantly more frequently in patients with large right to left shunt which was present at 
rest (38 of 80, 47.5%), compared with patients who had a smaller shunt (four of 40, 10%) or 
with patients with no shunt at all (11 of 80, 13.8%). The prevalence of migraine without aura 
was similar in all groups. Authors concluded that migraine with aura was associated with 
presence or absence of PFO but also with the shunt size (21). 
McCandless et al (2011) conducted pediatric study involved a population consisted of 109 
children with migraine; 38 (35%) with aura and 71 (65%) without aura. The overall PFO 
prevalence was 35%, similar to the general population (35% vs. 25%; P = .13). However, 
compared with the general population (25%), the PFO prevalence was significantly greater 
in subjects with aura (50%, P = .0004) but similar in those without aura (27%, P = .73). Atrial 
shunt size was not associated with the presence or absence of aura. Their conclusion was 
that Children with migraine with aura have a significantly higher prevalence of PFO 
compared with those without aura or the general population. These data suggest that PFO 
may contribute to the pathogenesis of migraine with aura in children and have implications 
for clinical decision making (22). 
A meta analysis of 7 studies in adult population with migraine headache and aura showed 
association of PFO in this particular population ranging from 41- 62% (composite of 56% by 
meta-analysis) (23-29). 
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On the other hand; NOMAS study (30) involved screening of population from Northern 
Manhattan area showed no significant association of PFO with Migraine headache 
population. This study has several limitations though. It included only non-stroke patients 
who are older than 39 years, they used Trans thoracic Echocardiography for the screen of 
PFO with no Trans Cranial Doppler evaluation of the bubble study and they depended on 
self-reporting headache with obvious recall bias. 
Table one summarized the major studies of PFO association with Migraine headache. It is 
clear from all previously mentioned studies that Migraine with Aura has higher association 
of PFO compared to migraine without aura. Both (with and without aura) has higher 
prevalence of PFO compared to general population please see Table 1. 
 
  Migraine With Aura, Migraine Without Aura, 
Study PFO Method n/N (%) n/N (%) 
Del Sette et al TCD 18/44 (41) NA 
Anzola et al TCD 54/113 (48) 12/53 (23) 
Schwerzmann et al TEE 44/93 (47) NA 
Dalla Volta et al TCD 161/260 (62) 12/74 (16) 
Carod-Artal et al TCD 25/48 (52) 32/93 (34) 
Domitrz et al TCD 33/61 (54) 15/60 (25) 
NOMAS TTE 26/140 (19) 4/38 (11) 
TCD indicates transcranial Doppler; TEE, transesophageal echocardiography.  
Table 1. Prevalence of PFO Among Subjects With Migraine Selected From the Literature 
The prevailing hypothesis regarding the pathogenesis of migraine is an inherited 
excitability of certain brain networks that, when triggered by particular endogenous or 
exogenous factors, leads to a cascade of events that result in head pain. The presence of 
PFO might trigger this process by allowing substances or metabolites to pass from the 
hepatic or portal circulation to the carotids circulation. Migraneurs have increased platelet 
activation and aggregation in response to serotonin. Normally serotonin is metabolized by 
lung mono amino oxidase (MAO), but if blood is shunted through a PFO and avoids the 
pulmonary circulation it has been postulated that this can trigger migraine onset and 
precipitate aura (31). Another mechanism could possibly be transient hypoxemia caused 
by the PFO, causing subclinical infarcts in the brain, leading to irritation and propensity 
for migraines. Naqvi et al. report different manifestations of PFO including resting and 
stress hypoxemia related to left to right shunting across a PFO in the absence of 
pulmonary hypertension (32). 
4. Results of studies of PFO closure to relief migraine headaches 
Initial observation from studies involves Stroke prevention by PFO device-closure, showed 
patients with Migraine headaches improve after the procedures (34-38).  
Recently Wahl et al (2010) reported a large cohort of Migraneurs (150 patients 96 of them 
had aura) who underwent closure of PFO for stroke prevention. Of those 34% showed 
complete resolution of the headache and 48% showed significant improvement of their 
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headaches, making total of 82% of the migraneurs benefited from the closure. The presence 
of aura was associated with higher improvement in their study population. Still they 
showed improvement in non-aura migraneurs. 
Daniela Trabattoni reviewed 305 patients who underwent closure of their PFO for stroke 
prevention, 77 of them have migraine headache (~55% are female). Follow up of these 
migraine patients at 3 months showed complete cessation of headache in 46% of the 
patients and 40% had improvement of their headache intensity score ( total improvement 
of 86% of the patients). They found maintenance of these results up to 5 years of follow  
up (44).  
After these initial observations of improved migraine headache in the patients who 
underwent prevention of stroke by device-closure of their PFO (table 2), then several studies 
were conducted primarily for Migraine headaches relief. 
 
Table 2. Meta Analysis of 11 studies reported by Gianfranco Butera et al (40) 
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Luciane Piazza et al. evaluated 42 patients with migraine headache (28 with aura and 14 
without aura) after PFO closure for the migraine headache as a primary reason. After 6 
months follow up they found complete resolution of the migraine in 26%, and significant 
improvement in 52% of the study group. Interestingly they found patients improvement 
(total 78%) regardless of the presence of aura history. Multiple logistic regression analysis 
showed that the improvement in migraine with aura and migraine without aura was 
independent of migraine type, sex, age, cerebrovascular risk factors and cerebrovascular 
events, type of cardiac defect, and thrombophilic conditions (41). 
Another study by Andreas Wahl and his group was conducted on 17 patients with Migraine 
headache underwent closure of the PFO primarily for the headache reason (no stroke). They 
found total improvement in 71% of their patients with complete resolution of the headache 
in 26%. Their follow up was up to 30 months. They found slightly higher improvement in 
patients with aura (42). 
Gianluca Rigatelli et al. conducted prospective study on 34 patients with Migraine headache 
(22 females and 12 male) and underwent closure of the atrial defect by one of two devices 
(Amplatz cribriform, AGA PFO device or Premere Occlusion System). They found about 
55% of their study group have moderate to large atrial septal aneurysm. After a median of 9 
months follow up period they have significant improvement in all the patients with 20 
patients stopped completely their anti headache medications and the rest have improvement 
with less number of their medications (43). 
The only randomized prospective study with patients blinded for PFO closure conducted for 
migraine headache is MIST trial. They included about 147 patients randomized for device 
closure or Sham procedure (patients will have general anesthesia with incision in the groin 
without device implantation). The study had an ambitious primary end point which was 
complete cessation of Migraine headache in 40% of the patients who receive PFO device 
closure. They chose STARFlex® and they have much higher rate of complications in their 
study (~12%) compared to other PFO device studies. They showed in 6 months no statistical 
difference between the two groups in complete cessation of Migraine headache. Post-hoc 
analysis revealed that, when two extreme outliers were removed, a significant reduction in the 
median total headache days was observed in patients assigned to PFO closure (P = 0.027). A 
number of methodological reasons could explain why the primary end point of the MisT trial 
was not achieved. First, this ambitious primary end point, presumably selected to justify the 
risks of an interventional procedure, was so strict as to be unrealistic, and was arguably less 
clinically relevant than a quantifiable reduction in headache days. Although the path 
physiology of migraine is not fully elucidated, the probable multifactorial nature of migraine 
triggers means that correction of one potential trigger is unlikely to result in headache cure. 
Second, the patients for whom migraine improvement was previously reported had PFO 
closure for either cryptogenic stroke or decompression illness. However, such patients were 
specifically excluded from the MIST trial. The amount of residual shunt in MIST trial was 
extremely high (~35%) in 6 months follow up probably due to inherent device limitations used 
in the study. Other potential confounding factors include the ‘hangover effect’ of antiplatelet 
therapy and the difficulty of distinguishing between cardiac-level and pulmonary-level shunt 
when using transthoracic echocardiography (TTE). nonetheless, as the first randomized, 
controlled trial of its kind, the MIST trial has pioneered a robust study design for PFO closure 
trials and raised questions to be addressed in future studies. 
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In Summery: The association of migraine headache with Patent Foramen Ovale is higher 
than normal population (more than double) by most of the studies. Trans Cranial Doppler 
has higher sensitivity than Echo (TTE, TEE or ICE) in detecting the right to left shunt across 
the atrial septum. Because of the anatomical orientation of the Inferior Vena Cava towards 
the Foramen Ovale, injection of bubble contrast in lower limbs veins might be higher 
sensitive than injection in upper limbs veins. Whether the PFO/Migraine association means 
also a causation relationship: a question still needs more definite answer. Most of the studies 
(from stroke studies and primary studies for Migraine relief) are pointing towards the 
causation relationship. Although the only randomized prospective study in the literature 
failed to show a definite answer, several confounding factors (as mentioned above in the 
text) can explain the negativity of this study. Most of the studies showed higher response 
and benefit to patients suffer from Migraine with aura compared to others. 
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